TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Study of the Effect of omega3 on Biomarkers of Cardiac Necrosis (CKMB and Troponin I) and Inflammation Marker (CRP) After Elective Percutaneous Coronary Intervention (PCI)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* candidate of elective PCI~* treatment with aspirin at least 5 days before PCI~Exclusion Criteria:~* high CKMB and troponin I level~* cardiac bypass in recent 3 months~* platelet count \< 70×10 9/L~* sever chronic renal failure~* active bleeding~* treatment with glycoprotein IIb/IIIa inhibitors during PCI~* treatment with bivalirudin during PCI~* sensitivity to aspirin and clopidogrel

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- omega 3 (Type: ACTIVE_COMPARATOR): receive omega 3 in addition to standard treatment
- control (Type: NO_INTERVENTION): This group is without omega 3 : just receives standard treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Behavioral and Pharmacologic Treatment of Binge Eating and Obesity: Maintenance Therapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Participated in acute treatment for binge-eating disorder and obesity;~* Had a positive response to acute treatment;~* Available for the duration of the treatment and follow-up (20 months);~* Read, comprehend, and write English at a sufficient level to complete study-related materials; and~* Able to travel to study location (New Haven, CT) for monthly visits.~Exclusion Criteria:~* Currently taking anti-depressant medications;~* Currently taking opioid pain medications or drugs;~* Currently taking medications that influence eating/weight;~* History of seizures;~* Current substance use disorder or other severe psychiatric disturbance (e.g., suicidality);~* Past or current anorexia nervosa, bulimia nervosa;~* Pregnant or breastfeeding;~* Medical status judged by study physician as contraindication.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- NB medication (Type: EXPERIMENTAL): Participants randomly assigned to this arm will receive 16 weeks of NB medication. NB medication will combine naltrexone sustained-release (SR, 32 mg/day) combined with bupropion SR (360 mg/day) taken daily in pill form.
- Placebo (Type: PLACEBO_COMPARATOR): Participants randomly assigned to this arm will receive 16 weeks of placebo. Placebo will be inactive and taken daily in pill form.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Cerebral Blood Flow During Propofol Anaesthesia

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients planned for major abdominal surgery that require placement of an arterial line and central venous catheter, including oesophageal- or ventricular resection~* Age ≥ 18 years.~Exclusion Criteria:~* No informed consent~* Robotic assisted procedures~* Treatment with anti-inflammatory medication, including NSAID and corticosteroids~* Atherosclerosis of the internal carotid artery that obstructs ≥ 30% of the vessel lumen~* Neurologic disease considered to affect cerebral blood flow, including dementia, epilepsy, and apoplexy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Study of cerebral blood flow (Type: None): Patients undergoing oesophageal- or ventricular resection (n=30)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Exenatide Versus Glimepiride in Patients With Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosed with type 2 diabetes mellitus.~* Treated with diet and exercise and a stable, maximally tolerated dose of metformin for at least 3 months prior to screening.~* HbA1c \>=6.5% and \<=9.0%.~* Body Mass Index (BMI) \>=25 kg/m\^2 and \<40 kg/m\^2.~Exclusion Criteria:~* Participated in an interventional medical, surgical, or pharmaceutical study within 30 days prior to screening.~* Characteristics contraindicating metformin or glimepiride use.~* Receiving drugs that directly affect gastrointestinal motility.~* Receiving chronic (lasting longer than 2 weeks) systemic glucocorticoid therapy.~* Have used any prescription drug to promote weight loss within 3 months prior to screening.~* Treated for longer than 2 weeks with any of the following medications within 3 months prior to screening: \*insulin; \*thiazolidinediones; \*alpha-glucosidase inhibitors; \*sulfonylurea; \*meglitinides

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Exenatide (Type: EXPERIMENTAL): None
- Glimepiride (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Low-Dose Theophylline During Chronic Obstructive Pulmonary Disease (COPD) Exacerbations

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Severe COPD according to GOLD guidelines~* Age between 40 and 75~* Admission to hospital due to COPD exacerbation~Exclusion Criteria:~* History of asthma~* Pulmonary embolism~* Pneumonia~* Other chronic inflammatory disease~* Patient on theophylline at the time of admission~* Patient on oral steroids at the time of admission

- Gender: MALE
- Minimum Age: 40 Years
- Maximum Age: 75 Years
- Healthy Volunteers: t

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): Low-dose theophylline on top of standard therapy for COPD exacerbation
- 2 (Type: NO_INTERVENTION): Standard therapy for COPD exacerbation

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Hepatitis B Virus (HBV) Viral Suppression by Entecavir in Adefovir Partial Responders

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: OTHER
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
KEY INCLUSION CRITERIA:~* Age 18 years or older~* All genders and ethnicity~* Positive HBsAg~* HBeAg positive and negative~* Pretreatment HBV DNA of 10,000 copies/mL or higher (for purposes of this study, both copies and equivalent IU measurements will be recorded and analyzed)~* Patients who are switched to, or prescribed, entecavir after treatment with adefovir for at least 12 weeks by the providing physician.~* Patients with and without prior lamivudine exposure will be enrolled but enrollment of lamivudine experienced cases will be limited to no more than 30 patients total~KEY EXCLUSION CRITERIA:~* Patients who refused to consent to the study~* Patients younger than 18~* Vulnerable subjects such as pregnant women, prisoners, employees, patients with significant cognitive deficits.~* Patients with prior exposure to another nucleoside for more than 2 weeks. Those with prior exposure to lamivudine will be enrolled under conditions detailed above.~* HIV co-infection~* HCV co-infection~* HDV co-infection~* Recipients of solid organ transplantation~* Patients who receive high-dose steroid (60 mg/d or higher and for longer than 10 days)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group 1 (Type: None): Persistent viremia after 48 weeks or longer.
- Group 2 (Type: None): \<2 log IU/mL drop from initial HBVDNA after 12 weeks of adefovir
- Group 3 (Type: None): Patients who responded to adefovir and were switched to entecavir.
- Group 4 (Type: None): Patients with 160 copies/mL (100 IU/mL) or higher at the time of medication switch.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Androgen Replacement Therapy in Women With Hypopituitarism

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion criteria:~* Hypogonadism and/or hypoadrenalism of central origin~* Testosterone or free testosterone level below the median for age-matched normal controls~* Prior estrogen preparation for at least 6 months~Exclusion criteria:~* Any disease known to affect bone metabolism, including untreated hypothyroidism or hyperthyroidism~* Change in thyroid hormone dose in the last 3 months~* Untreated Cushing's syndrome~* Renal failure~* Alcoholism~* Anorexia nervosa~* Prior use of medication known to affect bone metabolism (e.g., supraphysiologic doses of glucocorticoids, phenytoin, bisphosphonates, or calcitonin) within the past 3 months~* Pregnant or nursing~* Uncontrolled hypertension~* ALT greater than 3 times upper limit of normal~* Serum creatinine greater than 2 times the upper limit of normal~* Any contraindication to estrogen therapy, including history of breast cancer or undiagnosed uterine bleeding~* Concurrent growth hormone replacement therapy, if patient has been receiving it for less than 2 years

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate AMG 162 in the Prevention of Postmenopausal Osteoporosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Eligibility Criteria~- Postmenopausal women with Osteopenia (lumbar spine bone mineral density T-score between 1.0 and -2.5)

- Gender: FEMALE
- Minimum Age: None
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- AMG 162 (Type: EXPERIMENTAL): 60 mg/mL denosumab given day 1, month 6, month 12 and month 18
- Placebo (Type: PLACEBO_COMPARATOR): Placebo given day 1, month 6, month 12 and month 18

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparing a Fatherhood Focused Individual Intervention to Batterer Intervention to Reduce IPV and Child Maltreatment

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* A reported an incident of IPV (pushing, slapping, kicking) within the last 12 months prior to screening (based on court/police records, partner or self- report);~* have at least one biological child aged 6 months to 7 years with whom they have contact in person or by phone/facetime etc. at least monthly;~* are able to complete assessments in English;~* agree to have their female coparents (mother of the youngest child) contacted as collateral informants and for consent for participation of their shared child.~Exclusion Criteria:~* Men who have an active full/no contact protective order pertaining to their child since this will preclude participation in the father-child play assessment (many men will have full no-contact orders with their partners, but it is more common for men to still be allowed at least supervised contact with their children even with a full/no contact order with their partner);~* physiological addiction to a substance that requires detoxification. Fathers will be evaluated using the Addiction Severity Index and urine toxicology screens. If fathers report difficulties with physiological withdrawal from substances (e.g. delirium tremens, shaking, nausea) they will be referred for detox services. They can be re-evaluated following a detox program with documentation from the detox center of successful completion and clean urine screen.;~* anyone with a cognitive impairment that will not allow for understanding of the study interventions (a mini mental state score \<25);~* anyone with a current untreated psychotic disorder;~* anyone currently suicidal or homicidal based on screening using the BSI.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- F4C (Type: EXPERIMENTAL): Participants randomized to the Fathers for Change (F4C) program.
- BIP (Type: ACTIVE_COMPARATOR): Participants randomized to the Batterer Intervention Program (BIP).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Interferon-Alpha for Diabetes Mellitus Type 1

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
* INCLUSION CRITERIA:~T1DM of less than 6 weeks duration in patients between 3 and 25 years of age.~Besides T1DM, no concurrent illness.~EXCLUSION CRITERIA:~Treatment with immunosuppressive or immunostimulatory medications such as azathioprine, nicotinamide, superoxide dismutase-desferroxamine, aminoguanidine, oral insulin or other experimental therapies at the present time or in the past.~Abnormal pre-treatment white blood cell count (WBC) or thrombocytopenia.~Known active diseases, e.g. cardiac, renal, hepatic diseases or immunodeficiency.~History of cancer, neuropathy seizure disorders (except typical history of febrile seizures in childhood), peripheral vascular disease, coagulation abnormalities, autoimmune disease (except type 1 diabetes) or cerebrovascular disease.~Ongoing use of medications known to influence glucose tolerance (e.g. sulfonylureas, metformin, diphenylhydantoin, thiazide or other potassium depleting diuretics, beta-adrenergic blockers, niacin) except insulin.~Any medical condition that, in the opinion of the investigator, will interfere with the safe completion of the trial.~Inability to give informed consent or assent.~Participation in a clinical trial within the previous 6 weeks.~Lactating or pregnant female individual (individuals will be advised not to volunteer for the protocol if they plan to become pregnant during the time of the study and they are instructed to use an effective method of contraception).~Age above 25 years, since there may be several subtypes of T1DM.

- Gender: ALL
- Minimum Age: 3 Years
- Maximum Age: 25 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): placebo was prepared as saline alone with 6mg human serum albumin (HSA). Subjects orally ingested one vial each morning before breakfast with at least 150mL water.
- 5,000 Units hrIFN-alpha (Type: EXPERIMENTAL): hrIFN-alpha = human recombinant interferon-alpha. 5,000 units was prepared along with saline and 6mg HSA. Subjects orally ingested one vial each morning before breakfast with at least 150mL water.
- 30,000 hrIFN-alpha (Type: EXPERIMENTAL): 30,000 units hrIFN-alpha was prepared along with saline and 6mg HSA. Subjects orally ingested one vial each morning before breakfast with at least 150mL water.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Sofosbuvir/Velpatasvir Fixed-Dose Combination and Ribavirin for 12 or 24 Weeks in Participants With Chronic Genotype 1 or 2 Hepatitis C Virus Infection Who Have Previously Failed a Direct-Acting Antiviral-Containing Regimen

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~* Genotype 1 or 2 HCV infection~* Chronic HCV infection (≥ 6 months prior to screening) documented by prior medical history or liver biopsy~* Previously treated with a DAA-containing regimen of at least 4 week duration~Note: Other protocol defined Inclusion/Exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- SOF/VEL FDC + RBV 12 weeks (Type: EXPERIMENTAL): SOF/VEL FDC + RBV for 12 weeks in participants with genotype 1 or 2 HCV infection
- SOF/VEL FDC + RBV 24 weeks (Type: EXPERIMENTAL): SOF/VEL FDC + RBV for 24 weeks in participants with genotype 1 or 2 HCV infection

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Immunogenicity, Safety and Tolerability of Two Doses of a Pre-pandemic Influenza Vaccine in Participants Aged 6 Months to 17 Years

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy subjects~Exclusion Criteria:~* Receipt of Seasonal Influenza Vaccine for season 2007/2008~* Receipt of another vaccine within 3 weeks before and after each vaccination~* Previous vaccination with a pandemic candidate vaccine and/or vaccine containing the adjuvant MF59 or a similar adjuvant~* Children who are in the local recommendation for influenza vaccination due to underlying diseases

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: 17 Years
- Healthy Volunteers: t

Study Arms:
- Arm 1 (Type: EXPERIMENTAL): 0.5mL of H5N1 vaccine 7.5ug
- Arm 2 (Type: ACTIVE_COMPARATOR): 0.25 or 0.5mL of H5N1 vaccine

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient has type 2 diabetes mellitus~* Patient has an HbA1c of ≥ 6.5 % and ≤ 10.0% and is currently using one of the following treatment regimens: A) Treatment with 0-3 oral antihyperglycemic agents B) Insulin therapy, either alone or in combination with up to two oral agents~* Female patients must not be breast feeding and agree to use an effective method of contraception or must not otherwise be at risk of becoming pregnant.~Exclusion Criteria:~* Patient has a diagnosis of type 1 diabetes mellitus, or a history of ketoacidosis.~* Patient has ever been treated with an approved or investigational GLP-1 receptor agonist.~* Patient is enrolled in another experimental protocol which involves the use of an investigational drug or device, or an intervention that would interfere with the conduct of the trial.~* Patient has a planned or anticipated revascularization procedure.~* Pregnancy or planned pregnancy during the trial period.~* Patient has end-stage renal disease or an estimated glomerular filtration rate (eGFR) of \<30 mL/min/1.73m2.~* Patient has a history of gastroparesis or pancreatitis.~* Personal or family history of medullary thyroid cancer or MEN2 (Multiple EndocrineNeoplasia Type 2) or calcitonin level of \>40 ng/L at baseline.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 130 Years
- Healthy Volunteers: f

Study Arms:
- Exenatide Once Weekly (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete